Skip to Content
Merck
CN

Key Documents

View All Documentation

F6127

Fludrocortisone acetate

synthetic, ≥98%, glucocorticoid activity, powder

Synonym(s):

9α-Fluoro-11β,17α,21-trihydroxy-4-pregnene-3,20-dione acetate, 9-Fluorocortisol acetate, 9-Fluorohydrocortisone acetate

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C23H31FO6
CAS Number:
514-36-3
Molecular Weight:
422.49
NACRES:
NA.77
PubChem Substance ID:
24894899
UNSPSC Code:
12352200
EC Number:
208-180-4
MDL number:
MFCD00864160
Assay:
≥98%
Form:
powder
Quality level:
100
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Fludrocortisone acetate, ≥98%

biological source

synthetic

Quality Level

100

sterility

non-sterile

assay

≥98%

form

powder

solubility

acetone: 50 mg/mL, clear, colorless to light yellow

shipped in

ambient

storage temp.

room temp

SMILES string

CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C

InChI

1S/C23H31FO6/c1-13(25)30-12-19(28)22(29)9-7-16-17-5-4-14-10-15(26)6-8-20(14,2)23(17,24)18(27)11-21(16,22)3/h10,16-18,27,29H,4-9,11-12H2,1-3H3/t16-,17-,18-,20-,21-,22-,23-/m0/s1

InChI key

SYWHXTATXSMDSB-GSLJADNHSA-N

Gene Information

human ... NR3C2(4306)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Fludrocortisone acetate is secreted by adrenal cortex. It increases the reabsorption of sodium and secretion of potassium and hydrogen. Fludrocortisone is used to treat cerebral salt wasting syndrome and adrenal insufficiency. Fludrocortisone improves the sensitivity of blood vessels to catecholamines and increases the blood volume.

Biochem/physiol Actions

Fludrocortisone acetate is a synthetic corticosteroid with more mineralocorticoid than glucocorticoid activity.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Warning

hcodes

H302,H361

Hazard Classifications

Acute Tox. 4 Oral - Repr. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCG3165
BCBV4395
BCBR1170V
BCBR1170
BCBQ4707V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Autonomic Neurology (2014)
G G Krishna et al.
Kidney international, 43(5), 1097-1103 (1993-05-01)
Potassium depletion induced by dietary potassium restriction causes sodium retention while potassium supplementation augments urinary sodium excretion. The role of external potassium balance in modulating mineralocorticoid-induced sodium retention in humans is unknown. Accordingly, eight healthy subjects were studied at the
Stéphane Gibaud et al.
International journal of pharmaceutics, 269(2), 491-508 (2004-01-07)
Substitutive hormonal therapies have to be administered for long periods. Thus, the development of sustained-release forms, as microparticle suspensions, is interesting in order to improve patient compliance by reducing dosing frequencies and side effects. The aim of this work was
Ichiro Nakagawa et al.
Cerebrovascular diseases (Basel, Switzerland), 35(2), 131-137 (2013-02-15)
Hyponatremia is a common complication occurring in one third of patients after subarachnoid hemorrhage (SAH). One mechanism that likely mediates the development of hyponatremia in SAH is cerebral salt wasting syndrome (CSWS), which induces natriuresis and reduces total blood volume
Dong-Min Kim et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 22(11), 3273-3276 (2007-07-10)
Hyperkalaemia is a commonly encountered problem in dialysis patients with end-stage renal disease (ESRD). The aim of the present study was to assess the effect of fludrocortisone acetate (FCA) on reducing serum potassium levels in haemodialysis (HD) patients with hyperkalaemia.
View All Related Papers

Global Trade Item Number

SKUGTIN
F6127-1G04061826236581
F6127-5G04061832850153

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service